203 related articles for article (PubMed ID: 3259680)
21. [Results of CA-125 tumor marker determination in patients with ovarian carcinoma].
Miladinović D; Paunović R; Paunković N
Jugosl Ginekol Perinatol; 1989; 29(3-4):83-5. PubMed ID: 2601371
[TBL] [Abstract][Full Text] [Related]
22. [Value of CA 125 in comparison to conventional tumor markers in ovarian cancer].
Paulick R; Kaesemann H; Caffier H
Geburtshilfe Frauenheilkd; 1986 Aug; 46(8):509-14. PubMed ID: 2875919
[TBL] [Abstract][Full Text] [Related]
23. Ovarian vein vs peripheral blood CA125 serum levels: a comparative study.
Podnos YD; Gamboa G; Kurosaki T; Buller R; Walker JL; Manetta A
Gynecol Oncol; 1997 Jul; 66(1):71-4. PubMed ID: 9234924
[TBL] [Abstract][Full Text] [Related]
24. [The value of CA 125 determination in the serum of patients with ovarian cancer].
Bartel U; Johannsen B; Elling D
Zentralbl Gynakol; 1989; 111(5):301-9. PubMed ID: 2728673
[TBL] [Abstract][Full Text] [Related]
25. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer.
Hefler LA; Concin N; Hofstetter G; Marth C; Mustea A; Sehouli J; Zeillinger R; Leipold H; Lass H; Grimm C; Tempfer CB; Reinthaller A
Clin Cancer Res; 2008 Feb; 14(3):710-4. PubMed ID: 18245530
[TBL] [Abstract][Full Text] [Related]
26. The serum concentrations of TAG-72 antigen measured with CA 72-4 IRMA in patients with ovarian carcinoma. Preliminary data.
Gadducci A; Ferdeghini M; Ceccarini T; Prontera C; Facchini V; Bianchi R; Fioretti P
J Nucl Med Allied Sci; 1989; 33(1):32-6. PubMed ID: 2746365
[TBL] [Abstract][Full Text] [Related]
27. [Significance of CA 125 antigen levels in patients with ovarian cancer].
Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
[TBL] [Abstract][Full Text] [Related]
28. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
Oehler MK; Sütterlin M; Caffier H
Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
[TBL] [Abstract][Full Text] [Related]
29. [Immunosuppressive acidic protein (IAP) in gynecologic malignant tumors and its relationship with other immunosuppressive substances and cell-mediated immunity].
Takada M
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt):237-44. PubMed ID: 6881975
[TBL] [Abstract][Full Text] [Related]
30. [The CA-125 tumor marker in epithelial ovarian cancers of stage I].
Nagele F; Vavra N; Kurz C; Sevelda P
Wien Klin Wochenschr; 1993; 105(20):585-8. PubMed ID: 8259686
[TBL] [Abstract][Full Text] [Related]
31. [Immunosuppressive acidic protein in patients with gynecologic cancer].
Sawada M; Matsui Y; Okudaira Y; Shimizu Y; Takayama K
Nihon Sanka Fujinka Gakkai Zasshi; 1983 May; 35(5):605-11. PubMed ID: 6408203
[TBL] [Abstract][Full Text] [Related]
32. Clinical evaluation of tumor-associated mucin-type glycoprotein CA 54/61 in ovarian cancers: comparison with CA 125.
Suzuki M; Sekiguchi I; Tamada T
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):422-7. PubMed ID: 2381620
[TBL] [Abstract][Full Text] [Related]
33. Plasma lipid-associated sialic acid and serum CA 125 as indicators of disease status with advanced ovarian cancer.
Vardi JR; Tadros GH; Foemmel R; Shebes M
Obstet Gynecol; 1989 Sep; 74(3 Pt 1):379-83. PubMed ID: 2761915
[TBL] [Abstract][Full Text] [Related]
34. [Variations in the level of immunosuppressive acidic protein in patients with gynecologic tumors and pregnant women].
Sawada M; Okudaira Y; Matsui Y; Miyoshi Y; Takayama K; Shimizu Y; Miura S
Gan To Kagaku Ryoho; 1983 Aug; 10(8):1823-30. PubMed ID: 6882005
[TBL] [Abstract][Full Text] [Related]
35. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer.
Einhorn N; Bast RC; Knapp RC; Tjernberg B; Zurawski VR
Obstet Gynecol; 1986 Mar; 67(3):414-6. PubMed ID: 2418395
[TBL] [Abstract][Full Text] [Related]
36. The role of acute-phase reactant proteins, carcinoembryonic antigen and CA 19-9 as a marker in the preoperative staging of colorectal cancer: a prospective clinical study.
Yüceyar S; Ertürk S; Dirican A; Cengiz A; Saner H
Int Surg; 1996; 81(2):136-9. PubMed ID: 8912078
[TBL] [Abstract][Full Text] [Related]
37. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
[TBL] [Abstract][Full Text] [Related]
38. [Studies on immunosuppressive acidic protein (IAP) in ovarian tumors].
Miyoshi T; Nishimura H; Hamai J; Yamada T; Tomoo Y; Kobayashi H; Yakushiji M; Kato T
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jun; 37(6):923-9. PubMed ID: 2991397
[TBL] [Abstract][Full Text] [Related]
39. [Evaluation of immunosuppressive acid protein in genitourinary malignant diseases].
Okada S; Kirime S; Kawasaki T; Kanbara A; Kanehara H; Takasaki N; Miyazaki S; Inai S
Hinyokika Kiyo; 1988 Mar; 34(3):411-8. PubMed ID: 3389287
[TBL] [Abstract][Full Text] [Related]
40. [Serologic monitoring of patients with endometrial carcinoma using ovarian carcinoma antigen (CA 125)].
Göcze P; Varhson H
Orv Hetil; 1993 Mar; 134(13):685-8. PubMed ID: 8460017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
